Latest News & Developments
Fortis Life Sciences Will Exhibit at SITC 2024
October 18, 2024
The Fortis Life Sciences® team is excited to welcome the immuno-oncology scientific community to our backyard when the Society for Immunotherapy of Cancer (SITC) annual meeting arrives in Houston, TX from November 8-9, 2024.
Fortis Life Sciences 2023 Highlights
January 1, 2024
Fortis Life Sciences is thrilled to recap a year of significant achievements and milestones in 2023. As a testament to our commitment to innovation and excellence, we are proud to highlight some of our key successes from the past year.
Fortis Life Sciences acquires International Point of Care
July 12, 2023
Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products.
Lunaphore and Bethyl Laboratories announce partnership to leverage library of primary antibodies on COMET™ platform and expand spatial biology services
May 10, 2023
Lunaphore and Bethyl Laboratories today announced a partnership to promote compatibility and expansion of Bethyl’s library of primary antibodies on Lunaphore’s COMET™ platform.
Fortis Life Sciences Partners with AccuGenomics to Expand Genomics Portfolio
March 29th, 2022
Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced it is the exclusive channel partner for AccuGenomics in the United States, with co-exclusive rights in Europe.
Fortis Life Sciences Acquires Abcore, a Leader in Single-Domain Antibody Technologies
March 2, 2022
Fortis Life Sciences has acquired Abcore, a San Diego, California, USA based antibody discovery platform specializing in single-domain antibody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma customers developing antibody and VHH-based therapeutics.
Fortis Life Sciences Highlights First Year Success
February 16, 2022
Company expands into key market verticals in diagnostics, therapeutics, and research discovery with solutions for proteins, genomics, and diagnostic assay development services.
Fortis Life Sciences Acquires nanoComposix
July 23, 2021
Fortis Life Sciences has completed its acquisition of nanoComposix, a premiere nanomaterials company focused on solutions for assay development and diagnostics. Since 2004, nanoComposix has built one of the most comprehensive nanomaterials portfolios in the industry. nanoComposix’s nanomaterials are used in a wide array of Life Sciences applications, including drug delivery, diagnostics and imaging, as well as industrial applications.
Fortis Life Sciences Acquires Bethyl Laboratories
March 10, 2021
Fortis Life Sciences, a life sciences company offering products and solutions for the life sciences industry, has acquired the premium antibody company Bethyl Laboratories. Based in Montgomery, Texas, Bethyl Laboratories has a long history of offering the highest quality primary and secondary antibodies to its customers, as well as other protein detection reagents. Bethyl Laboratories is well known for industry leading performance and the highest standards in antibody validation, and prior to the acquisition by Fortis, had successfully operated as a private, family-owned, and operated business for nearly 50 years.
Biocare Medical and Bethyl Laboratories Announces the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications
August 4, 2020
Biocare MedicalLLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.
Biocare Medical and Bethyl Laboratories Announce Strategic Partnership for Antibody Development
June 29, 2020
Biocare Medical a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces a collaborative partnership with Bethyl Laboratories to develop targeted antibodies for cancer research and oncology diagnostics.
New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
June 17, 2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration with Bethyl Laboratories to provide broader verified antibody access for researchers using Fluidigm’s Imaging Mass Cytometry™ (IMC™) technology.
